Ftse Mib
34.266,44
-0,32%
DAX
18.504,05
-0,52%
S&P 500
5.631,22
0,28%
NASDAQ
18.472,57
0,40%
Bitcoin
63.138,27
-2,65%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ALX Oncology Holdings Inc (ALXO) ALX Oncology Holdings Inc (ALXO) Notizie

ALXO

ALX Oncology (ALXO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALXO
DataOraFonteTitoloSimboloCompagnia
07/06/202211:40TipRanksStifel Nicolaus Thinks ALX Oncology Holdings’ Stock is Going to RecoverNASDAQ:ALXOALX Oncology Holdings Inc
03/06/202213:00GlobeNewswire Inc.ALX Oncology Announces Evorpacept Clinical Program UpdatesNASDAQ:ALXOALX Oncology Holdings Inc
01/06/202213:00GlobeNewswire Inc.ALX Oncology to Participate in the Jefferies 2022 Healthcare ConferenceNASDAQ:ALXOALX Oncology Holdings Inc
27/05/202222:59Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:ALXOALX Oncology Holdings Inc
16/05/202212:16TipRanksH.C. Wainwright Thinks ALX Oncology Holdings’ Stock is Going to RecoverNASDAQ:ALXOALX Oncology Holdings Inc
09/05/202222:18Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALXOALX Oncology Holdings Inc
09/05/202222:01GlobeNewswire Inc.ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:ALXOALX Oncology Holdings Inc
22/04/202214:28Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ALXOALX Oncology Holdings Inc
15/04/202201:54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALXOALX Oncology Holdings Inc
15/04/202201:50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALXOALX Oncology Holdings Inc
12/04/202214:35Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALXOALX Oncology Holdings Inc
12/04/202213:00GlobeNewswire Inc.ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of DirectorsNASDAQ:ALXOALX Oncology Holdings Inc
25/03/202221:45Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:ALXOALX Oncology Holdings Inc
02/03/202213:00GlobeNewswire Inc.ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction CancerNASDAQ:ALXOALX Oncology Holdings Inc
28/02/202222:57Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ALXOALX Oncology Holdings Inc
28/02/202213:58Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ALXOALX Oncology Holdings Inc
28/02/202213:00GlobeNewswire Inc.ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming MilestonesNASDAQ:ALXOALX Oncology Holdings Inc
09/02/202215:11Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ALXOALX Oncology Holdings Inc
04/02/202215:13Edgar (US Regulatory)Schedule 13gNASDAQ:ALXOALX Oncology Holdings Inc
28/01/202200:43Dow Jones NewsALX Oncology Gets FDA Orphan Drug Designation for EvorpaceptNASDAQ:ALXOALX Oncology Holdings Inc
27/01/202223:51GlobeNewswire Inc.ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction CancerNASDAQ:ALXOALX Oncology Holdings Inc
10/01/202212:00GlobeNewswire Inc.ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022NASDAQ:ALXOALX Oncology Holdings Inc
04/01/202213:00GlobeNewswire Inc.ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALXOALX Oncology Holdings Inc
17/12/202122:58Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ALXOALX Oncology Holdings Inc
14/12/202115:00PR Newswire (US)DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter GarciaNASDAQ:ALXOALX Oncology Holdings Inc
14/12/202112:16TipRanksH.C. Wainwright Reiterates a Buy Rating on ALX Oncology Holdings (ALXO)NASDAQ:ALXOALX Oncology Holdings Inc
12/12/202115:00GlobeNewswire Inc.ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic SyndromeNASDAQ:ALXOALX Oncology Holdings Inc
11/11/202122:05GlobeNewswire Inc.ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:ALXOALX Oncology Holdings Inc
09/11/202113:00GlobeNewswire Inc.ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid TumorsNASDAQ:ALXOALX Oncology Holdings Inc
04/11/202114:00GlobeNewswire Inc.ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual MeetingNASDAQ:ALXOALX Oncology Holdings Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALXO

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
FBK
Finecobank
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
RACE
Ferrari NV
BIT
ENI
Eni
BIT
BC
Brunello Cucinelli
BIT
PRY
Prysmian
BIT
SPM
Saipem
BIT
G
Generali
BIT
MONC
Moncler
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network